.Attributes Medication, Posted online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec obtained FDA permission after an unfavorable trial, which highlights the various complications as well as challenges of medication growth in this setup.